Transcript Slide 1

Leaders in
Contract Manufacturing
Registered Office
20th Floor, Lotus Business Park, Off Andheri Link Road, Andheri (West), Mumbai - 53
Contact No: +91-22-4068 2300 (30 Lines), Fax: +91-22-4068 2323/33, 2673 3687
Website: www. ankurdrugs.com Email: [email protected]
INTRODUCTION
• A Public Limited Company listed at Bombay Stock Exchange &
National Stock Exchange of India Limited having a turnover of INR
10675 million and Net profit of INR 894 million
• Engaged in the manufacturing of Pharmaceutical Formulations
since 1998.
• Multi location facility having Plants at Daman and Baddi
• The company’s major expansion program with a view to cater the
International Market.
• Ankur is privileged of being in the forefront of contract
manufacturing with India’s leading and multinational
pharmaceutical companies.
INTRODUCTION
•
Ankur’s first plant is situated at Daman, which is having dedicated block for
General and Beta-lactum products in oral dosage form.
•
The Company has set-up two plants spread across “dimensions” at Himachal
Pradesh in excise and pollution free zone, amongst lush green surroundings.
The main object behind setting up two units was to cater Domestic and
International Market.
•
Ankur has succeeded to explore and maintain its production target for above
400 different formulations for different dosage forms – viz Tablets, Capsules,
Dry Syrups, Liquid Orals, etc.
•
Company has already received WHO GMP Certification for its Unit - I at Village
Manakpura, Tehsil : Nalagarh, Dist.: Solan, Himachal Pradesh – 173 205.
To manufacture and supply quality
healthcare products at reasonable
prices to our customers.
“Our focus is to meet and exceed
stakeholders expectations.”
APPROACHES AND VALUES
Strong Business Ethics
Transparent Operations
Passion for Performance
High Customer Value
Team of Experienced Pragmatic People.
BADDI UNIT –I : OVERVIEW
•
Project envisaged in Jan 2005
•
Set up to meet the challenges in the new Taxation scenario
•
Capital Investment of US$ 35.00 million = INR 175 Crores
•
WHO / GMP approved plant
INFRASTRUCTURE
Land Area
Twelve Acres
General Block 1
50X40 meters Block : Ground + Service Floor
General Block 2
42X85 meters Block : Ground + Three Floors
Cephalosporin Block
30X45 meters Block : Ground + Three Floors
Beta-Lactum Block
30X45 meters Block : Ground + Three Floors
Warehouse Block 1
50X90 meters Block : Ground + Three Floors
Utilities
35X15 meters Block : Ground + Service Floor
BADDI UNIT –I : PRODUCTION FACILITIES :
•
Unit is having manufacturing facilities with modular clean room panels for General
Products, Beta-lectum Products and Cephalosporin Products in oral dosage forms. Each
block is having dedicated Quality Control Laboratories. The manufacturing area of all blocks
are maintained at class 100,000.
•
In General Block, Oral Liquid filling and packaging line are connected to fully automatic
cartoning and case packing machine from Romaco, Italy.
•
Betalactum and Cephalosporin Blocks are having low RH (<25%) manufacturing areas with
continuous monitoring systems from Rotronic, Switzerland. Both the Dry Syrup filling and
packaging lines of Betalactum and Cephalosporin Blocks are having on-line non-destructive
leak testing machines for filled and sealed bottles from Bonfiglioli, Italy giving the
advantage of 100% check on sealed containers and fully automatic cartoning and case
packing machine from Romaco, Italy.
•
State-of-the-art technology built-up viz : Capsule Filling Machine, Automatic Tablet Coating
Machine from Sejong and Alu Alu Blister Pack Machines from Hoonga, Korea have been
installed in all critical area.
BADDI UNIT – I:
INSTALLED CAPACITY p.a ( in million) :
GENERAL BLOCK :
Tablets (Coated / Uncoated)
Capsules
Liquid Orals
3000.00
375.00
150.00
CEPHALOSPORIN BLOCK:
Tablets (Coated / Uncoated)
Capsules
Dry - Syrups
Insta use Suspensions
480.00
144.00
24.00
24.00
BETA LACTUM BLOCK:
Tablets Uncoated
Capsules
Dry - Syrups
Insta use Suspensions
480.00
1248.00
48.80
24.00
BADDI UNIT –II : OVERVIEW
•
Designed as per USFDA / MHRA standards
•
Capital Investment of US$ 120 million = INR 550 Crores
•
Technical arrangement with : BASSAIRE – UK , a leading consulting firm, Engineers &
Architect.
INFRASTRUCTURE
Land Area
Fifteen Acres
General Block
77 x 77 meters Block : Ground + First Floor +
Two Service Floor
Cephalosporin Block
77 x 54 meters Block: Ground + Service Floor
Q.C. Central Warehouse
77 x 24 meters Block : Ground + Three Floor
& Admin Block
Utility Block
67 x 17 meters Block Ground + First Floor
BADDI UNIT – II : HIGH END TECHNOLOGY
• There is a high focus onwards automation to avoid human intervention and
errors occurred thereon and in the process, various standard machineries
are imported to meet the requirements.
• In General Block and Cephalosporin Block Tablet Compression and Capsule
Filling machine are from Sejong, Korea. Alu Alu Blister Pack machine from
Hoonga, Korea, fully Automatic Strip Pack machine from Siebler, Germany
and all packaging lines are connected to fully automatic cartoning and case
packing machine from Hoonga and Romaco, Italy.
• In EVT area, single pot manufacturing equipment is from Zanchetta, Italy and
fully Automatic Strip Pack machine from Siebler, Germany and fully
automatic cartoning and case packing machine from Romaco, Italy.
BADDI UNIT – II : HIGH END TECHNOLOGY
• Ointment filling line and Sterile Dry Powder filling line from Romaco
Macofar, Italy are connected to fully automatic cartoning and case
packing machine from Romaco, Italy.
• As a major step towards Ankur’s progress in International market,
Trans Dermal Patches (Fentanyl and Cold Fleece) and Oral Strip
(Ondansetrone, Donepezil – Hcl, Ketotifen Fumarate, Baclofe,
Rivastigmine, Sildenafil Citrate, Glimepiride and Olanzapine) are
ready for manufacturing, in technical colaboration with Labtech Germany and Applied Pharma Research – Switzerland for marketing
in India and various South Asian territories. .
BADDI UNIT – II : PRODUCTION FACILITIES
•
State-of the art technology built-in. High degree of automation which is one of its
kind in India and South East Asia, having dedicated manufacturing blocks for
General Products and Cephalosporin Products with modular cleanroom panels
from Thrislington, U.K and designed as per USFDA/MHRA norms.
•
General Block is having manufacturing facility of Tablets, Capsules, Effervescent
Tablet, Liquid Injections, Ointments, FFS, Trans Dermal Patches and Oral Film
Products.
•
Cephalosporin Block is having manufacturing facility of Tablets, Capsules, Dry
Syrups and Sterile Dry Powder Injections.
•
The Manufacturing areas of Oral Dosage Forms and Ointment are maintained at
Class 1,00,000 and manufacturing area of Liquid Injection and Sterile Dry Powder
Injections are maintained at class 100.
BADDI UNIT – iI:
INSTALLED CAPACITY p.a ( in million) :
GENERAL BLOCK
Tablets - coated / uncoated
9,000.00
Capsules
900.00
Liquid Injectables
144.00
Effervescent Tablets
300.00
Sachets
60.00
Ointments/Creams
30.00
Form Fill and Seal (FFS)
30.00
CEPHALOSPORIN BLOCK
Tablets coated / uncoated
Capsules
1200.00
540.00
Dry Syrups
48.00
Dry powder Injectables
30.00
•
Mr. Purnandu Jain - Chairman and Managing Director, is a qualified
Chartered Accountant having over Ten years of experience in Pharma
manufacturing business. He has successfully turned around the company
and improved its performance many fold.
•
Mr. Girraj Vijayvargiya - Executive Director, is also a qualified Chartered
Accountant having over 10 years experience in Pharmaceutical Project
Finance and Purchase.
•
Mr. A. Hossain - President (Technical & Projects), M. Pharm. Having over 28
years of experience in Projects, Manufacturing, Plant Administration.
•
Mr. Jayesh Trivedi – Chief Operating Officer, B. Pharm. Having over 30 years
of experience in techno commercial, outsourcing & business development,
mainly responsible for regulatory affairs & International business.
•
Mr. M. B. Sawant - Sr. Vice President (Commercial), M.B.A. Production, having
about 30 Years experience in PPC and Supply Chain in pharmaceutical industry.
•
Mr. Sunil Soni - Vice President (Operations), M. Pharm. Having over 17 years
experience in Manufacturing and Plant Administration.
•
Mr. Sardul Singh - General Manager (Administration) having more than 45
years experience in the Industry.
•
Mr. Ashok Mehta - General Manager (Quality Assurance), M. Pharm having
more than 26 years of experience in the Industry.
SOME OF OUR VALUED CUSTOMERS
(as per alphabetical order)
•
Abbott India Limited
•
Piramal Healthcare Limited
•
Blue Cross Laboratories Limited
•
Pfizer India Ltd
•
Cipla Limited
•
Rajasthan Drugs &
Pharmaceuticals Limited
•
Dr. Reddy’s Laboratories Limited
•
Ranbaxy Laboratories Limited
•
Sandoz Private Limited
•
Sanofi Aventis
Karnataka Antibiotics &
Pharmaceuticals Limited
•
Torrent Pharma Limited
Novartis India Limited
•
USV Limited
•
•
•
•
Hindustan Antibiotics Limited
Hovid
ANKUR REVOLUTIONIZING CANCER TREATMENT
•
Fentanyl Transdermal Patch – A breakthrough in pain management therapy in
treatment of cancer
•
High end pain management drug
•
Painless dosage form
•
Reduced dosage form due to quick absorption and high efficacy
•
Fentanyl a potential goldmine
•
Ankur has exclusive manufacturing and marketing rights of Fentanyl in territories
such as South –East Asia, South Africa, East Africa and Central Africa
ANOTHER FIRST FOR ANKUR
•
Ankur will be the first ever Indian company to launch “Rapid Film” in India and other
territories. The company has been granted exclusive manufacturing rights for initial
15 years for territories viz. India, Bangladesh, Sri Lanka, Pakistan and Afghanistan
•
Is a new concept in oral dosage form and medication.
•
It is a novel, non-muco adhesive fast dissolving oral dosage form.
•
It releases the drug in the mouth and initiates buccal absorption, within no time.
•
Any drug up to 50 mg per strip can be easily taken up through this dosage form. The
film is either packed in conventional ways or in elegant single smart card design, such
as credit card format.
•
Ankur has associated with Optimags Germany for an exclusive special coating lines
and has imported the latest technology in Packing lines from “Siebler” (Romaco
Group) Germany viz Rapid film for Ondasetrone, Donepezil-Hcl, Ketotifen Fumarate,
Baclofe, Rivastigmine, Sildenafil Citrate, Glimepiride and Olanzapine.
FINANCIAL HIGHLIGHTS OF LAST 5 YEARS
SUMMARY OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED
(Rs. Crores)
PARTICULAR'S
Net Sales/Income from Operations
31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010
136.45
373.24
673.50
Other Income
0.07
0.32
1.50
Increase in Inventory
0.40
6.62
3.30
136.92
380.18
678.30 1,014.60 1072.88
104.16
302.76
542.19
784.42
799.38
Manufacturing Expenses
8.10
15.98
21.67
33.02
39.52
Administrative, Sales and Other Expenses
2.66
3.15
6.16
14.98
19.14
114.92
321.89
570.02
832.42
858.04
Total Income
965.32 1067.53
1.6
2.94
3
46.34
3.72
TOTAL EXPENDITURE
Materials Consumed
Total Expenditure
FINANCIAL HIGHLIGHTS OF LAST 5 YEARS
SUMMARY OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED
(Rs. Crores)
PARTICULAR'S
Profit before depreciation, finance cost and tax
Less: Depreciation
Less: Interest and Financial Charges
Less: Prov. for exch. diff. on foreign currency loans
Less: Prov for premium on redemption of FCCB's
Less: Other Misc. Provisions
Profit before tax
Less: Provision for taxation
- Current Tax
- Deferred Tax
- Fringe Benefit Tax
Profit after tax
Dividend (Including Dividend Tax and prov for prev. yr.)
Earning per share
- Basic (In Rs.)
- Diluted (In Rs.)
31/03/2006
31/03/2007
31/03/2008
31/03/2009
22.00
2.50
4.08
-
58.29
6.01
12.92
-
108.28
8.40
24.86
-
182.18
20.67
54.10
26.13
20.94
1.42
31/03/2010
214.84
26.77
79.00
(16.23)
3.20
(1.33)
15.42
39.36
75.02
58.92
1.36
0.05
0.03
4.25
2.32
0.05
8.71
2.74
0.07
7.30
14.39
0.10
21.00
13.00
-
13.98
32.74
63.50
37.13
89.43
1.62
2.22
5.65
5.01
-
14.72
34.43
53.79
19.94
46.24
17.62
23.50
23.61
37.63
-
123.43
SUMMARY OF BALANCE SHEET AS AT
(Rs. Crores)
PARTICULAR'S
Sources of Funds
Shareholders' Funds
Equity Share Capital
Equity Share Application and Warrants
Reserve & Surplus
Miscellaneous Expenditure
Deferred Tax Liability
Net Worth
Loan Funds
Term Loan (Secured)
Working Capital Loan
Loan from Directors (Unsecured)
Loan from Others (Unsecured)
Foreign Currency Convertible Bonds
Current Liabilities & Provisions
Current Liabilities
Provisions
TOTAL LIABILITIES
31/03/2006
31/03/2007
31/03/2008
31/03/2009
31/03/2010
9.50
10.56
12.70
18.61
19.34
---
8.07
8.72
10.02
---
19.32
94.53
198.04
243.01
345.23
(0.25)
(0.37)
(0.52)
(0.26)
-
4.82
7.14
9.88
24.27
37.27
33.39
119.93
228.82
295.65 401.84
42.60
145.20
236.89
205.28
258.65
26.15
82.25
168.33
274.76
392.52
2.41
1.87
1.33
1.40
39.86
66.90
76.77
116.62
114.05
-
55.07
134.16
145.43
125.71
7.11
4.40
26.40
6.69
38.78
13.68
60.57
33.35
96.88
52.54
156.23
504.81
899.41
1,134.27
1.50
1443.69
SUMMARY OF BALANCE SHEET AS AT
(Rs. Crores)
PARTICULAR'S
31/03/2006 31/03/2007 31/03/2008 31/03/2009 31/03/2010
Application of Funds
Fixed Assets
Gross Block
41.15
127.96
228.04
390.65
775.16
8.16
15.58
23.88
44.50
71.28
Net Block
32.99
112.38
204.16
346.15
703.88
Capital Work-in-progress
65.61
245.03
331.49
266.10
22.94
0.01
0.02
5.24
3.74
0.48
Inventories
24.56
62.18
123.15
212.77
322.97
Sundry Debtors
28.35
76.90
163.91
281.14
357.69
Cash and Bank Balances
1.74
2.56
59.06
15.84
7.01
Loans and Advances
2.97
5.74
12.40
8.53
28.72
TOTAL LIABILITIES
156.23
504.81
899.41
1,134.27
1443.69
Current Ratio
1.53
1.28
1.62
1.41
1.32 : 1
Debt Equity Ratio
2.88
2.64
2.53
2.38
2.22 :1
Less: Depreciation
Investments
Current Assets, Loans and Advances
SUMMARY OF PROJECTIONS
2010 - 11
2011 - 12
2012 - 13
2013 -14
(Rs. Crores)
2014 - 15
Net Sales
1350.00
1500.00
1600.00
1700.00
1750.00
EBI DTA
243.00
270.00
288.00
306.00
315.00
PBT
130.00
150.00
175.00
190.00
200.00
PAT
100.00
120.00
135.00
145.00
150.00
18%
18%
18%
18%
18%
NET PROFIT MARGIN
7.41%
8%
8.44%
8.53%
8.57%
CASH PROFIT MARGIN
11.11%
11.33%
11.50%
11.47%
11.43%
PROFITABILITY RATIO %
OPERATING PROFT MARGIN